1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, U10CA098543, NCT01096368
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
3.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 21 Sponsor: Other Protocol IDs: CMH 09C4, NCT01088035
|
|
5.
|
Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: 1 to 25 Sponsor: NCI, Other Protocol IDs: 10-206, NCT01288235
|
|
6.
|
Phase: Phase I Type: Treatment Status: Active Age: 3 to 22 Sponsor: Pharmaceutical / Industry Protocol IDs: 07-098, NCT00634231
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 19 at diagnosis Sponsor: NCI Protocol IDs: NCI-2011-02539, 10-C-0219, CDR0000687467, NCI-10-C-0219, 8449, NCT01226940
|
|
8.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 at diagnosis Sponsor: Other Protocol IDs: SJYC07, SJCRH-SJYC07, NCT00602667
|
|
9.
|
Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 2 to 25 Sponsor: Other Protocol IDs: 2005P001629, NCT01115777
|
|
10.
|
Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569
|